Business Description
Biomark Diagnostics Inc
NAICS : 621510
SIC : 8681
ISIN : CA09073K1084
Description
Biomark Diagnostics Inc is developing its early-stage cancer diagnostic technology platform. It is cancer diagnostics technology platform leverages "Omics" and machine learning with a focus on how to detect and treat cancers. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.4 | |||||
Equity-to-Asset | 0.18 | |||||
Debt-to-Equity | 2.19 | |||||
Debt-to-EBITDA | -0.7 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 7.63 | |||||
Beneish M-Score | -3.9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.6 | |||||
3-Year EBITDA Growth Rate | 14.5 | |||||
3-Year EPS without NRI Growth Rate | 20.6 | |||||
3-Year FCF Growth Rate | 3.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.96 | |||||
9-Day RSI | 54.12 | |||||
14-Day RSI | 50.42 | |||||
3-1 Month Momentum % | -7.02 | |||||
6-1 Month Momentum % | 12.77 | |||||
12-1 Month Momentum % | 59.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.99 | |||||
Quick Ratio | 0.99 | |||||
Cash Ratio | 0.92 | |||||
Days Sales Outstanding | 911.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.1 | |||||
Shareholder Yield % | 0.17 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2428.33 | |||||
Net Margin % | -2460 | |||||
EBITDA Margin % | -1720 | |||||
FCF Margin % | -1824.32 | |||||
OCF Margin % | -1835.14 | |||||
ROE % | -154.59 | |||||
ROA % | -63.26 | |||||
ROIC % | -191.01 | |||||
3-Year ROIIC % | -192.31 | |||||
ROC (Joel Greenblatt) % | -315.77 | |||||
ROCE % | -120.2 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 560 | |||||
PB Ratio | 186.67 | |||||
EV-to-EBIT | -41.42 | |||||
EV-to-EBITDA | -56.75 | |||||
EV-to-Revenue | 976.07 | |||||
EV-to-FCF | -53.53 | |||||
Earnings Yield (Greenblatt) % | -2.41 | |||||
FCF Yield % | -1.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biomark Diagnostics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.037 | ||
| EPS (TTM) (€) | -0.018 | ||
| Beta | -1.1145 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 0.86 | ||
| Volatility % | 44.16 | ||
| 14-Day RSI | 50.42 | ||
| 14-Day ATR (€) | 0.010617 | ||
| 20-Day SMA (€) | 0.3159 | ||
| 12-1 Month Momentum % | 59.8 | ||
| 52-Week Range (€) | 0.191 - 0.42 | ||
| Shares Outstanding (Mil) | 105.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biomark Diagnostics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biomark Diagnostics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Biomark Diagnostics Inc Frequently Asked Questions
What is Biomark Diagnostics Inc(STU:20B)'s stock price today?
The current price of STU:20B is €0.32. The 52 week high of STU:20B is €0.42 and 52 week low is €0.19.
When is next earnings date of Biomark Diagnostics Inc(STU:20B)?
The next earnings date of Biomark Diagnostics Inc(STU:20B) is .
Does Biomark Diagnostics Inc(STU:20B) pay dividends? If so, how much?
Biomark Diagnostics Inc(STU:20B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Biomark Diagnostics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers